Impact of a 2-yr anti-TNF treatment on the quality of life in JIA patients: a parent's/patient’s view

Similar Items

• The use of Etanercept and Adalimumab in the management of JIA: a 5-year follow-up study
  od: Trachana, M, i dr.
  Izdano: (2008)
• The role of synovial fluid cytokines IL-6, IL-23 and IL-17 in the pathogenesis and persistence of synovial inflammation in JIA patients
  od: Tzimouli, V, i dr.
  Izdano: (2008)
• PReS-FINAL-2093: Can clinical response within 12 weeks in JIA-etanercept receivers predict the future clinical remission?
  od: Pratsidou-Gertsi, P, i dr.
  Izdano: (2013)
• The portrait of Familial Mediterranean Fever in N. Greek pediatric patients: a 30-year experience
  od: Pratsidou-Gertsi, P, i dr.
  Izdano: (2015)
• A biopsychosocial approach to parents of children with juvenile idiopathic arthritis
  od: Georgiadou, Z, i dr.
  Izdano: (2011)